Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 3/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.33 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | CHEK1 | O14757 | 3/20 | 0.32 |
| ▸ | CHEK2 | O96017 | 3/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14748866 | 0.83 | BAZ2B (0.41) | BAZ2BHTTHPGDNCOA1NCOA3 | |
| SCHEMBL880222 | 0.80 | BAZ2B (0.47) | BAZ2BHTTHPGDNCOA1NCOA3 | |
| SCHEMBL14748859 | 0.75 | BAZ2B (0.31) | BAZ2B | |
| SCHEMBL24298768 | 0.75 | HTT (0.38) | BAZ2BHTTHPGDNCOA1NCOA3 | |
| SCHEMBL22343436 | 0.74 | HTT (0.35) | BAZ2BHTTTSHRCHEK1CHEK2 | |
| SCHEMBL22343410 | 0.74 | HTT (0.37) | BAZ2BHTTHPGDNCOA1NCOA3 | |
| SCHEMBL10313033 | 0.73 | BAZ2B (0.42) | BAZ2BHTTHPGDNCOA1NCOA3 | |
| SCHEMBL12395230 | 0.73 | BAZ2B (0.42) | BAZ2BHTTHPGDNCOA1NCOA3 | |
| SCHEMBL6370890 | 0.73 | BAZ2B (0.42) | BAZ2BHTTHPGDNCOA1NCOA3 | |
| SCHEMBL14748858 | 0.73 | BAZ2B (0.41) | BAZ2BHTTHPGDNCOA1NCOA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1428827-B1 | Derivatives of 2,2'-Di (3,4-alkylenedioxythiophen) their preparation and use | HERAEUS PRECIOUS METALS GMBH (DE) | 2012-03-28 | — | — | EP | disclosed |
| EP-2319848-A1 | 2,2'-Di (3,4-alkylenedioxythiophene) derivatives and their use for the preparation of 2,2'-Poly-(3,4-alkylendioxythiophene)-Derivatives | H.C. Starck Clevios GmbH (DE) | 2011-05-11 | — | — | EP | disclosed |
| US-7102016-B2 | Preparation of 2,2′-di(3,4-ethylenedioxythiophene)s | H. C. STARCK GMBH (DE) | 2006-09-05 | — | — | US | disclosed |
| US-20040122239-A1 | Preparation of 2,2'-di(3,4-ethylenedioxythiophene)s | HERAEUS PRECIOUS METALS GMBH & CO. KG (DE) | 2004-06-24 | — | — | US | disclosed |
| EP-1428827-A1 | Derivatives of 2,2'-Di (3,4-alkylenedioxythiophen) their preparation and use | H.C. Starck GmbH (DE) | 2004-06-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040122239-A1 | Preparation of 2,2'-di(3,4-ethylenedioxythiophene)s | SULT1E1, SULT1A1, TPST2 | BAZ2B 4529/4885HTT 1728/4885HPGD 786/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.